Pauwels et al described a number of phenotypic changes that occur in a gastrointestinal stromal tumor (GIST) following prolonged therapy with imatinib mesylate. Recognition of these changes can prevent misdiagnosis. The authors are from Maastricht Academic Medical Center, University of Leuven, University Hospital in Gasthuisberg and Catholic Hospital of Leuven in the Netherlands and Belgium.
